Cadent Therapeutics to Present at Upcoming Investor Conferences - Aug. 28, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Cadent Therapeutics, a company focused on the development of therapies to improve the lives of patients with movement and cognitive disorders, today announced that Jodie Morrison, the Company’s Chief Executive Officer, will present at the following upcoming investor conferences:

Citi’s 14^th Annual Biotech Conference
Date: Wednesday, September 4, 2019
Panel: 3:45 p.m. ET
Location: Four Seasons Boston

Morgan Stanley’s 17^th Annual Global Healthcare Conference
Date: Tuesday, September 10, 2019
Presentation: 2:05 p.m. ET
Location: Grand Hyatt New York

About Cadent Therapeutics

Cadent Therapeutics is creating therapies for the treatment of movement disorders and cognitive impairment. The company combines target specificity, patient selection, drug design and optimization, and novel quantitative endpoints to create first-in-class molecules to treat movement and cognitive disorders. Cadent Therapeutics is rapidly advancing its pipeline of positive allosteric modulators to treat spinocerebellar ataxia, essential tremor and schizophrenia. The company has an exclusive license and collaboration agreement with Novartis to develop a negative allosteric modulator, now in Phase 2 for the treatment of treatment resistant depression. Investors include Atlas Venture, Cowen Healthcare Investments, Qiming Venture Partners, Access Industries, Clal Biotechnology Industries, Novartis Institutes for Biomedical Research and Slater Technology Fund. For more information, please visit cadenttx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190828005172/en/